Interleukin 10 and Heart Fatty Acid-Binding Protein as Early Outcome Predictors in Patients With Traumatic Brain Injury
Kaj Blennow; Linnéa Lagerstedt; Virginia F. J. Newcombe; Henna-Riikka Maanpää; Jussi P. Posti; Ari J. Katila; Peter J. Hutchinson; Iftakher Hossain; Mark van Gils; Jussi Tallus; David K. Menon; Jean-Charles Sanchez; Olli Tenovuo; Leire Azurmendi; Henrik Zetterberg; Riikka S. K. Takala
Interleukin 10 and Heart Fatty Acid-Binding Protein as Early Outcome Predictors in Patients With Traumatic Brain Injury
Kaj Blennow
Linnéa Lagerstedt
Virginia F. J. Newcombe
Henna-Riikka Maanpää
Jussi P. Posti
Ari J. Katila
Peter J. Hutchinson
Iftakher Hossain
Mark van Gils
Jussi Tallus
David K. Menon
Jean-Charles Sanchez
Olli Tenovuo
Leire Azurmendi
Henrik Zetterberg
Riikka S. K. Takala
FRONTIERS MEDIA SA
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2021042825326
https://urn.fi/URN:NBN:fi-fe2021042825326
Tiivistelmä
Background:Patients with traumatic brain injury (TBI) exhibit a variable and unpredictable outcome. The proteins interleukin 10 (IL-10) and heart fatty acid-binding protein (H-FABP) have shown predictive values for the presence of intracranial lesions. Aim:To evaluate the individual and combined outcome prediction ability of IL-10 and H-FABP, and to compare them to the more studied proteins S100 beta, glial fibrillary acidic protein (GFAP), and neurofilament light (NF-L), both with and without clinical predictors. Methods:Blood samples from patients with acute TBI (all severities) were collected 6 months post injury using the Glasgow Outcome Scale Extended (GOSE) score, dichotomizing patients into: (i) those with favorable (GOSE >= 5)/unfavorable outcome (GOSE <= 4) and complete (GOSE = 8)/incomplete (GOSE <= 7) recovery, and (ii) patients with mild TBI (mTBI) and patients with TBIs of all severities. Results:When sensitivity was set at 95-100%, the proteins' individual specificities remained low. H-FABP showed the best specificity (%) and sensitivity (100%) in predicting complete recovery in patients with mTBI. IL-10 had the best specificity (50%) and sensitivity (96%) in identifying patients with favorable outcome in patients with TBIs of all severities. When individual proteins were combined with clinical parameters, a model including H-FABP, NF-L, and ISS yielded a specificity of 56% and a sensitivity of 96% in predicting complete recovery in patients with mTBI. In predicting favorable outcome, a model consisting IL-10, age, and TBI severity reached a specificity of 80% and a sensitivity of 96% in patients with TBIs of all severities. Conclusion:Combining novel TBI biomarkers H-FABP and IL-10 with GFAP, NF-L and S100 beta and clinical parameters improves outcome prediction models in TBI.
Kokoelmat
- Rinnakkaistallenteet [19207]